Systematic reviews: what they are, why they are important, and how to get involved by MacKenzie, Heather et al.
[  193  ]
Reviews
(narrative/literature/traditional)
Systematic reviews
Meta-analyses
Figure 1. Types of reviews.
Basic research for clinicians
Systematic Reviews: What They Are, Why They Are 
Important, and How to Get Involved
Heather MacKenzie, PhD., Ann Dewey, PhD., Amy Drahota, PhD., Sally Kilburn, PhD., 
Paul R Kalra, MA, FRCP, MD, Carole Fogg, MSc., Donah Zachariah, MBBS, MRCP, Portsmouth, Hampshire, UK
This article introduces systematic reviews and their purpose, and considerations in understanding and appraising reviews. The processes involved in planning and 
conducting a review are summarized, and resources for new reviewers are listed. (J Clin Prev Cardiol 2012;1(4):193-202)
  Key Words: Systematic review; meta-analysis; forest plot; overview; Cochrane.
ABSTRACT
From: School of Health Science and Social Work, University of 
Portsmouth, Portsmouth, Hampshire, UK, (H.M., An.D., Am.D., S.K, 
C.F.), Queen Alexandra Hospital, Cosham, Portsmouth Hospitals 
NHS Trust, Portsmouth Hampshire, UK (P.R.K., C.F., D.Z.,)
Corresponding Author: Carole Fogg, MSc. 
School of Health Science and Social Work, 
University of Portsmouth, Queen Alexandra Hospital, Cosham, 
Portsmouth Hospitals NHS Trust, Portsmouth, Hampshire, UK
Email: Carole.Fogg@port.ac.uk
Introduction to Systematic Reviews
What are systematic reviews?
A systematic review can be defined as “a review of a 
clearly formulated question that uses systematic and 
explicit methods to identify, select and critically appraise 
relevant research, and to collect and analyze data from 
the studies that are included in the review. Statistical 
methods (meta-analysis) may or may not be used to 
analyze and summarize the results of the included 
studies.” http://www.cochrane.org/glossary
Health care providers are constantly faced with the 
dilemma of achieving the 6R’s – the right person (a 
suitably qualified professional), doing the right thing 
(evidence-based practice), in the right way (skills and 
competence), at the right time (providing treatments/
services when the patient needs them), in the right place 
(location of treatments/services), with the right result 
(maximizing health gain) (1). The medical literature 
on which to base decisions is rapidly growing, but 
the reliability and relevance of the available research 
evidence varies in quality and application across different 
clinical scenarios. Health care providers need to be able 
to weigh the strengths and weakness of such evidence and 
summarize the findings to make an informed decision. 
For busy clinicians and health care providers, thank 
goodness for the systematic review! Systematic reviews 
attempt to summarize all past research to address a 
specific clinical question (or questions) using a systematic 
approach with methods that have been preplanned and 
documented in a systematic review protocol (2, 3). The 
types of questions systematic reviews aim to answer can 
vary significantly and the diverse nature of the available 
evidence demands the use of appropriate methodology 
to describe and synthesize these different types of 
evidence. These approaches include a comprehensive 
search of all potentially relevant articles and the use of 
explicit, reproducible criteria in the selection of articles 
for a systematic review.  Primary research designs and 
study characteristics are appraised, data synthesized 
and results interpreted (4). Statistical analysis (or meta-
analysis) may or may not be used to analyze the results 
of the included studies.  
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Narrative or literature views generally provide broad 
summaries on a topic – they are often invited contributions 
from experts in the field and can be opinion- based or 
formulated using selected literature without prespecified 
or documented methods. Systematic reviews on the 
other hand are far superior in that they adhere to a 
strict scientific design based on explicit, prespecified 
and reproducible methods (Table 1). By application of 
scientific strategies, it is possible to minimize error and 
bias to provide a more reliable and precise estimate of an 
intervention’s effectiveness. It may be considered that a 
large, appropriately powered and designed randomized 
study on its own may provide the answer to an important 
clinical question without the need for systematic review. 
However, all good research should begin and end with 
a systematic review and all available studies should 
be assessed, even if an apparently “definitive” trial is 
available.
Table 1.
Key differences between a systematic review and a narrative review
Systematic    Review Traditional Narrative 
Review
•	 Aims to minimize bias •	 May introduce bias through 
selective presentation of results
•	 Preplanned methodology with 
predefined outcome measures
•	 No preplanned methodology 
defining outcome measures
•	 A set search strategy •	 No set search strategy
•	 Comprehensive systematic 
searching including predefined 
databases and unpublished data 
•	 Often not predefined, 
systematic search of databases 
and does not include 
unpublished data
•	 Documented, explicit 
methodology so it is possible to 
replicate by another independent 
researcher
•	 Undocumented methodology 
which is difficult to replicate by 
another independent researcher 
•	 Systematic quality assessment of 
studies documented 
•	 Unlikely to include quality        
assessment of studies         
•	 Often involves a team of 
researchers
•	 Usually written by one expert/
researcher
•	 May include numerical 
aggregation of data (meta-
analysis) 
•	 Does not usually include 
statistical analysis
•	 Conclusions based on a series 
of set and predefined outcome 
measures
•	 Conclusions based (at best) on 
findings of the identified studies 
but more likely on the opinion 
of the reviewer
 (Adapted from Ref. 2, p.33.)
On completion of the systematic review, the methods 
used are documented in the review report, similar to 
that set out in primary research.  In this way, readers of 
the systematic review can see for themselves the steps 
taken to judge both the quality and reproducibility of 
the systematic review methods.  Systematic reviews 
can therefore provide the clinician with high-quality 
and timely research evidence to provide an answer to 
a focused clinical question (or questions).  Evidence 
thus becomes more accessible to not only health care 
providers but also their users, that is, patients and their 
families.
A recent development is the emergence of Overviews of 
Reviews (OoRs). Systematic reviews have a necessarily 
narrow focus (e.g., “hypothermia to reduce neurological 
damage following coronary artery bypass surgery,” Ref. 
5); however it may be more informative for clinicians to 
be able to access a summary of evidence from a range 
of related systematic reviews. This is the aim of an OoR. 
Using the above example, this systematic review might 
be included in a broader OoR which examines a range of 
interventions to reduce neurological damage following 
coronary artery bypass surgery (Figure 1). The methods 
of an OSR are similar to those of a systematic review 
with the exception that where systematic reviews focus 
on primary research studies, OoRs evaluate and combine 
information from systematic reviews.
History of systematic reviews
The emergence of the first systematic review is 
unknown, but can usually be attributed to one man – 
Professor Archie Cochrane (a Scottish epidemiologist) 
whose seminal text “Effectiveness and Efficiency” 
published in 1972 drew attention to the lack of reliable 
evidence on which to base health care decision.  Later 
when he wrote further text urging health practitioners to 
organize knowledge into a useable and reliable format 
and practice evidence-based medicine, others took up 
this challenge.  In the late 1970s and 1980s, a group of 
health service researchers in Oxford began a program of 
systematic reviews on the effectiveness of health care 
interventions followed in 1992 by the establishment 
of The Cochrane Collaboration – an international, 
independent and nonprofit organization committed to 
the principles of managing healthcare knowledge by 
publishing and updating high-quality systematic reviews 
was established.  Today, The Cochrane Collaboration 
maintains The Cochrane Database of Systematic 
Systematic Reviews: What They Are, Why They Are Important, and How to Get Involved Basic Research for Clinicians
[  195  ]
Reviews (CDSR) on The Cochrane Library – a database 
of systematic reviews and protocols, and comprises some 
53 review groups publishing protocols and systematic 
reviews on a variety of health-related topics, including 
The Cochrane Heart Group, Hypertension Group and 
Stroke Group. Other organizations with similar objectives 
have emerged, including the Australian-based  Joanna 
Briggs Institute (covering best evidence for global health 
care information), The Campbell Collaboration  (a sister 
organization to The Cochrane Collaboration) which 
provides systematic evidence for  issues of broader 
public policy, and the EPPI centre database providing 
well-designed evaluations of interventions in the fields 
of education and social welfare.  For more information 
on each of these organizations including access to 
resources and support offered, please refer to Table 2.  
Conducting a Systematic Review
When should I consider getting involved in a 
systematic review, and what commitment and 
skills are required? 
It may be that the answer to a clinical question you have 
cannot be found through an existing systematic review 
and hence you might consider embarking on your own 
review. There are many challenges and skills required 
for producing a systematic review. The skills required 
not only include having an understanding of the disease 
process, interventions, relevant outcomes and the patient 
experience; but also the ability to find and appraise all the 
relevant research, synthesize the findings using advanced 
statistical or qualitative techniques, and publish your 
findings. The processes of indexing retrieved studies, and 
extracting and managing the data can be daunting and 
some reviews will require specialist analytical software. 
Moreover, systematic reviews can be time-consuming 
and, depending upon the complexity of your question, 
typically take 1–2 years to complete. Perhaps for these 
reasons, many published systematic reviews are produced 
by teams working in collaboration with the support of a 
specialist systematic review organization (see Table 2) in 
order to achieve these many and varied tasks.  
What resources are available for clinicians 
intending to carry out a systematic review?
There are several specialist systematic review 
organizations; so what should you look for when 
selecting an organization to work with? Many first time 
reviewers, whether they are independent researchers or 
undertaking the review as part of a PhD or Professional 
Doctorate, feel that they benefit from attending 
workshops and accessing online training resources 
offered by some review organizations.  There are many 
possible approaches and techniques for a review so a 
review organization’s handbook and evidence-based 
guidance on the process could save you time. You will 
want the organization be up to date with good reporting 
practice, and to ensure that their guidance, handbooks 
and style guides help you to achieve these standards. 
As a researcher, you will probably want the opportunity 
to communicate and exchange ideas with people 
from a broad range of disciplines, and some review 
organizations provide seminars, conferences and online 
discussion rooms so creating a hub for a community. 
This kind of networking can be instrumental in acquiring 
the diverse skill mix required of coauthors to produce a 
well-researched and relevant review.  
The perspectives of those involved in the care for 
people with cardiovascular disease can be different to 
those of other health care professionals. As such the 
organization you choose to work with, or your own team 
or reviewers, should have strong input from relevant 
groups with appropriate expertise that can provide you 
with peer review and team members in order to achieve 
your review. Finally, one of your major goals will be to 
publish your findings, so look for an organization that 
will help you publish and make your review accessible 
to the public and professionals all over the world – 
perhaps without expensive journal registration fees. As 
part of the publishing process, you should expect peer 
review, copy editor support and the database or journal 
to be rated as of international standard. A summary of 
what support a nonexhaustive selection of organizations 
can provide for your review is given in Table 2.   More 
information on each can be found at
• Cochrane Collaboration: http://www.cochrane.org/
• Campbell Collaboration: http://www.
campbellcollaboration.org/
• Joanna Briggs Institute:  http://www.joannabriggs.
edu.au/
• Eppi centre:  http://eppi.ioe.ac.uk     
In addition, there are data repositories that provide 
support for registering your review protocol and 
systematic review data,  such as PROSPERO and the 
Systematic Review Data Repository (SRDR); these 
are easy to use web-based tools that extract and store 
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information. They serve as a public repository of 
data and have a searchable archive of key questions 
addressed by systematic reviews. More information 
can be found at: Systematic Review Data repository: 
http://srdr.ahrq.gov/; PROSPERO: http://www.crd.york.
ac.uk/prospero/.  In addition, many journals also publish 
systematic reviews, and some journals will additionally 
publish systematic review protocols, there are even now 
dedicated journals for systematic reviews (http://www.
systematicreviewsjournal.com/).
Steps of Doing a Systematic Review 
Including Writing a Suitable Protocol 
Whatever your choice of systematic review support 
organization, the methods of your review will follow 
commonly agreed steps as outlined in Figure 2.
For a systematic review to be deemed “systematic,” it 
needs to follow a set protocol, in order to be replicable, 
transparent, and (as much as possible) free from bias. 
The first stage of any systematic review should be to 
define the research question. Commonly for systematic 
reviews of the effectiveness of treatments, the question 
will follow a “PICOS” format (to define the Population, 
Intervention(s), Comparison(s), Outcomes and Study 
designs of interest to the review). These elements of 
the research question will be further set out through 
the eligibility criteria for the review. A protocol will be 
required to set out the types of research studies to be 
Cochrane Collaboration Campbell Collaboration Eppi Centre Joanna Briggs Institute
Training
Membership fee No No No Yes
Workshops Yes (mostly free) Not routinely Yes (Charge) Yes (charge)
Online training Yes Yes Yes Yes
Handbook or guidance document Yes Limited Yes Yes
Style guide Yes No Unclear No
Dissemination
Own journal or web-based 
database
Cochrane database of 
Systematic Reviews
Campbell Library Knowledge library JBI Library of Systematic 
Reviews
Conference or colloquium Yes yes - -
Impact factor (The 2011 Journal 
Citation Report, Thomson ISI)
5.715 - - -
Collaboration
Consumer and public 
involvement in peer review
Yes - - -
Cardiac related specialist group Heart Group No No Yes 
Contact with methodological 
specialists
Yes, including a number of 
Methods groups e.g. 
non-randomised trials 
Yes Yes specialize in methods to 
synthesis evidence for public 
policy 
-
Peer review Yes Yes Yes Unclear
Types of Review Supported
Qualitative or mixed 
methodology
Yes Yes Yes Yes
Screening and Diagnostic Yes Yes Yes Yes
Effectiveness questions Yes Yes Yes Yes
Topics Health care Education, criminal 
justice, social policy and 
social care
Those that inform policy and 
practice in social 
interventions
Clinical decision making
Table 2.
Potential resources for teams involved in systematic reviews
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included in the review, and anything that does not meet 
these criteria will be excluded, based on the prespecified 
research question and a sound rationale. Protocols 
will also set out how studies will be searched for, and 
how (and which) data will be collected, analyzed and 
combined. It is a good practice to publish systematic 
review protocols to enhance the transparency of the 
process and avoid duplication. This can be done either 
through conducting the review via an organization such as 
the Cochrane Collaboration, or Campbell Collaboration, 
by registering the protocol in a dedicated database such 
as PROSPERO (see link above), or through publishing 
with a journal. 
Having established the protocol, the next step is to 
search relevant electronic databases, reference lists 
and other sources as determined by the search strategy, 
to seek studies meeting the eligibility criteria. This 
would typically involve searching a range of relevant 
bibliographic databases using appropriate search terms, 
the reference lists of included studies and for grey 
literature (unpublished studies). The most comprehensive 
systematic reviews will also search for studies published 
in languages other than English, although this can 
be time- and cost-prohibitive. Omitting studies not 
published in English can introduce bias as can searching 
only for those published in academic journals (6). Note 
that even though all studies may appear to be retrieved, 
there are many studies which are not published due to 
nonsignificant results. Results of the search are screened 
against the eligibility criteria, typically by at least two 
independent people to avoid errors of judgment. Search 
results may be filtered by screening titles first, then 
abstracts of relevant-looking titles and finally the full 
reports. An audit trail is kept of the number of studies 
screened and excluded at each stage, and reasons for 
excluding studies which appeared relevant. You may 
find that systematic review software will help you to 
manage this stage (see Ref. 7 for further guidance on 
choosing appropriate software). It is not unusual to 
exclude large numbers of studies retrieved from the 
original search once the inclusion and exclusion criteria 
are fully considered. 
This can be appreciated in the illustrated example below 
where the effect of renin–angiotensin system blockade 
on mortality and hospitalization in heart failure with 
preserved ejection fraction (HF-PEF) is studied (8). 
Here, a systematic search of electronic databases 
(MEDLINE, PUBMED, EMBASE, and the Cochrane 
Library for Central Register of Clinical Trials) using the 
MESH terms – ‘‘heart failure, diastolic,”, ‘‘angiotensin-
converting enzyme inhibitors’’ (ACE-I), ‘‘angiotensin 
receptor antagonists” (ARB) and the names individual 
ACE(I)/ ARBs – was performed.  The search was 
limited to studies in human subjects and English 
language in peer-reviewed journals from 1966 to June 
2011. A manual search for relevant clinical studies from 
references of the screened articles was additionally 
carried out. The authors defined their eligibility criteria 
to be (a) prospective (randomized or nonrandomized) or 
retrospective study designs assessing the effectiveness 
of rennin–angiotensin system inhibitors (ACE-I or ARB) 
for HF-PEF (defined as signs or symptoms of heart 
failure and EF >40 %); (b) studies reporting outcomes 
of interest, including mortality (all-cause and/or cardiac) 
and hospitalizations due to heart failure; and (c) studies 
with at least a 6-month follow-up in each study arm. 
Exclusion criteria were (a) healthy persons used as 
Figure 2. Stages of a systematic review.
Define the research 
question
Set the eligibility criteria for 
included studies
Plan the methods of the 
review
 Search for studies
Screen studies against the 
eligibility criteria
Collect data and assess for risk 
of bias
Analyze and summarize 
results
Interpret results and draw 
conclusions
Update and improve review
Publish 
protocol
Publish 
review
Publish updated 
review
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controls, (b) patients following heart transplantation, 
(c) absence of quantitative description of end points, (d) 
lack of clear and reproducible results, and (e) trials in 
the abstract form without a published manuscript in a 
peer-reviewed journal. Studies that had duplicated data, 
including the same group of patients or for whom there 
were updated results available, were excluded. Figure 3 
illustrates this process, and is an example of application 
of the PRISMA (preferred reporting items for systematic 
reviews and meta-analyses) checklist (http://www.
prisma-statement.org/statement.htm).
deviation from the truth; it may overestimate or 
underestimate the true effect, and it may be large or 
small. Bias can be minimized during the conduct 
of studies (e.g., through randomizing participants, 
allocation concealment, blinding patients, researchers 
and healthcare personnel, withdrawals and drop-outs, 
reporting of outcomes, etc.), and these are tangible 
things that can be assessed in a systematic review to form 
judgments about the risk of bias, and how believable 
the results of the studies are. As with screening, the 
independent assessment by two review authors is a 
method to reduce bias in this process. If studies included 
in a review are at a high risk of bias, one may place 
less confidence in their findings. The data are then 
summarized through narrative and tables and, where 
appropriate, statistical tests to combine included studies 
(meta-analyses) may be undertaken to provide statistical 
summaries of the study results.
Where there is a high degree of heterogeneity (variability 
between studies, either in types of participants, 
interventions or outcomes, or study design, risk of bias 
or results), it may not be appropriate to combine their 
results using meta-analysis. This is sometimes referred 
to as being like combining apples and oranges (10). If 
there is reason to believe that the intervention would 
work differently in subgroups of the sample (e.g., 
populations at high or low risk), then subgroup analyses 
should also be conducted. Meta-analyses are typically 
presented in forest plots (see the next section for how to 
interpret these). Where meta-analysis is not appropriate, 
the results may be presented using tables and text. 
Prior to completing the review, it would be advisable to 
consider rerunning the search to check for any recently 
published studies that the first search may have missed. 
The interpretation of data and conclusions drawn should 
be grounded in the risk of bias of the included studies, 
so as to reflect the believability of the findings, as well 
as the direction and precision of results relating to the 
benefits and harms of the interventions assessed. All this 
information should then be written up in an accessible 
format to help inform practitioners, patients, policy-
makers, and others who may be interested in the review 
findings. It is a good practice to then keep your review 
up-to-date and consider republishing it every few years 
depending on the speed of progress in the field. It is 
possible at this stage that you need to go back to your 
protocol and reconsider if the methods are still fit-for-
purpose (Fig. 2).
Figure 3. Example flow diagram to illustrate study selection for 
systematic review of the effect of renin–angiotensin system blockade 
on mortality and hospitalization in heart failure with preserved 
ejection fraction (HF-PEF). 
Potentially relevant articles identified and 
screened for retrieval ( n = 112)
Excluded after reading title/abstract as did not 
satisfy inclusion criteria (n = 95)
Trials retrieved for more detailed evaluation ( n + 17)
Excluded: 
• Not evaluating outcomes of interest (n = 3) 
• Meta-analysis (n = 1) 
• Short duration of follow up (n = 1)
Studies included for final analysis (n = 12): 
• Randomized control trials (n = 5) 
• Observational studies (n = 7)  
  (Prospective - 4, retrospective - 3)
Hence for final analysis, only about 10% of the original 
selection of articles made it through the entire screening 
process. Data extraction is also often independently 
performed by two authors with disagreements being 
solved by arbitration and discussion. It is crucial to 
predefine criteria for study selection and data analysis to 
ensure transparency and reproducibility while generating 
an effective and meaningful systematic review. 
Next, data is collected from studies meeting the review 
criteria, to include information on PICOS characteristics, 
outcome data and risk of bias assessments. Risk of 
bias assessment should be done, when possible, using 
a predetermined, validated tool (or equivalent for 
qualitative studies if included) (9). Bias is a systematic 
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Reading and Critically Appraising 
Systematic Reviews 
Why is it important to critically appraise 
systematic reviews?
If there are existing systematic reviews that relate to your 
clinical question, you may be able to apply the findings 
of an existing review to your current practice rather than 
conduct a new review. Systematic reviews are currently 
considered as one of the highest forms of research 
evidence and it can be tempting to view a systematic 
review as providing “the definitive answer” to a clinical 
question. Those conducted under the auspices of the 
Cochrane Collaboration are held in particularly high 
regard (7) but on a general note, there are a number of 
reasons as to why caution is required in the interpretation 
and application of the findings of a systematic review.
Firstly, the quality of systematic reviews is variable (11). 
If a systematic review has not been well conducted, 
there would be concern regarding the validity of its 
findings. Secondly, even if a systematic review has 
been well-conducted it might have identified significant 
limitations or gaps in the current evidence base, and 
rightly recommend that its findings are interpreted with 
caution (although this is a good rationale for conducting 
some new research!). Similarly, a well-conducted 
systematic review might not have been recently updated 
and its findings might not therefore be based on current 
primary research. The inclusion of more recent studies 
has the potential to change the findings of the systematic 
review (12). A well-conducted systematic review might 
(for a number of reasons) have only included studies on 
participants very dissimilar to the patient(s) the clinician 
has in mind.  Should this be the case, there may be 
reasons to suspect that the findings are not applicable to 
the patient(s) in question. Hence, wherever a systematic 
review has been published, it is important to critically 
appraise it before using it to inform practice. 
What to consider when critically appraising a 
systematic review
 When critically appraising a systematic review, it is 
important to bear in mind the points made above about 
what steps should be followed in order to conduct a good 
systematic review. In addition, we would recommend 
that you use a structured critical appraisal checklist to 
help you appraise systematic reviews; for example, those 
published by the Critical Appraisal Skills Programme 
(www.casp-uk.net) or the AMSTAR questionnaire (13) 
are useful tools in the appraisal of systematic reviews. 
General types of questions often considered by such 
checklists include the following: 
• Is the review question focused and clear?
• Was the search comprehensive?
• Were studies selected in an unbiased manner?
• Was the risk of bias of included studies assessed?
• Were the data analyzed appropriately?
• Were the results presented appropriately?
• How, and should, I apply the findings of the 
systematic review to my practice?
There are two key questions you should ask when you 
are considering the implications of the findings of a 
systematic review for your practice. The first is “are 
the participants, intervention and outcome relevant 
to my clinical question?” It may be that the inclusion 
criteria of the systematic review do not cover the types 
of participants, interventions and/or outcomes in which 
you are interested. For example, the participants may not 
be similar to your patients or the setting may differ from 
that in which you work (e.g., community versus acute 
care), the intervention may not be one in which you 
are interested (perhaps it is not feasible to implement 
in your setting) and the outcomes may not be relevant 
(e.g., you may be interested in mortality but the review 
has considered only anxiety). It may also be, however, 
that the inclusion criteria do cover these but no relevant 
studies have yet been conducted. 
The second question is “what do the results mean for 
practice?” You should consider whether the intervention 
was more effective than the control and if so, examine 
the effect size – is the effect meaningful in clinical 
practice? Does the size of the effect outweigh the cost to 
implement the intervention? Also look at the confidence 
intervals (CIs) – if the true effect was at the upper or 
lower bound, would this change your decision about 
whether to implement the intervention? It is important 
to interpret these for yourself so that you can check 
whether the conclusions of the systematic review 
accurately reflect the findings. A further consideration 
is the type of studies on which the results have been 
based. For example, you might place more confidence 
in results that are based on randomized controlled trials 
at a low risk of bias than those at a high risk of bias or 
other study designs such as controlled before and after 
studies. It is worth checking that, based on issues around 
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risk of bias, you agree with the conclusions made by 
the systematic review authors. The GRADE approach 
provides guidelines for making recommendations 
based on research evidence, which you may find help 
you to consider how to interpret the findings of 
systematic reviews (see http://cebgrade.mcmaster.ca 
and http://www.gradeworkinggroup.org/guidelines/
index.htm  for further guidance).
Interpreting forest plots
Although not all systematic reviews conduct meta-
analyses, many do and present their findings in the form 
of forest plots. These present, for each comparison and 
outcome, both the study effects (and CIs) derived from 
individual studies and a pooled effect of all the studies. 
Forest plots may look complicated but do not be put off, 
because they are actually relatively simple to understand.
Study
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0.91 (0.73, 1.13) 156/7061 172/7082 35.93
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0.87 (0.77, 0.99) 429/22257 489/22185 100.00
0.26 (0.14, 0.50) 12/6076 45/6022 24.45
0.58 (0.37, 0.92) 29/7061 50/7082 34.94
0.51 (0.35, 0.75) 40/9120 78/9081 40.60
0.45 (0.31, 0.68) 81/22257 173/22185 100.00
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Figure 4. Forest plot for (A) all-cause stroke and systemic embolism, (B) ischemic and unspecified stroke, and (C) hemorrhagic stroke, new 
oral anticoagulants (NOA) versus warfarin in patients with atrial fibrillation (AF).
The example in Figure 4 illustrates the forest plot from a 
systematic review by Miller et al. looking at the efficacy 
and safety of newer anticoagulants versus warfarin 
for atrial fibrillation (14). The outcome measured here 
is all-cause stroke and systemic embolism, ischemic 
and unspecified stroke and hemorrhagic stroke. The 
rows of the forest plot represent the individual studies 
included for that comparison and outcome. On the left 
of the forest plot you will find a list of these included 
studies (commonly given a study ID consisting of the 
first author’s name and the year in which the study 
was published). The sample size for the control and 
intervention groups may also be given, as will either the 
mean scores (with standard deviations) for continuous 
outcomes such as blood pressure or the number of 
people with the outcome (e.g., number of people who 
had a cardiac arrest). The number of events may also 
be used (e.g., number of cardiac arrests) and can be 
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summarized using a rate ratio (for rare events), or mean 
difference (for common events). The information at the 
bottom of the forest plot relates to the data that has been 
pooled from all the included studies. There is generally 
a total sample size for control and intervention groups. 
The line that runs up the middle of the plot is called 
“the line of no effect.” For all effects represented by 
“ratios” (e.g., odds, risk, or hazards ratios) the line of 
no effect is placed at 1 on the horizontal axis. For all 
effects represented by absolute differences (e.g., mean 
differences), it is placed at 0. The square blocks represent 
the point estimate of the effect for each study (larger 
blocks indicate that the study was given more weight in 
the analysis, for example, because it had a larger sample 
size), and the horizontal lines the CIs. In a meta-analysis, 
studies with narrower CIs are given more weight in the 
analysis, and those with wider CIs are given relatively 
less weight; this is referred to as weighting according 
to the inverse of the variance. For ease of interpretation, 
the numerical data are also written in a table beside the 
forest plot. If you look at the diamond at the bottom of 
the plot, the middle of the diamond is the point estimate 
of the effect size and the widest points of the diamond 
represent the CIs:
• If the CIs cross the line of no effect, then the current 
evidence indicates that the intervention is neither 
more nor less effective than the control (it is possible 
that this estimate may change if new evidence is 
incorporated). 
• If the diamond is to the right of the line, and the 
CIs do not cross the line of no effect, then the 
intervention is indicated to increase the outcome of 
interest (the evidence will favor the control if the 
outcome is undesirable). 
• Conversely, if the diamond is to the left of the 
line, and the CIs do not cross the line of no effect, 
then the intervention has decreased the outcome of 
interest (the evidence will favor the intervention if 
the outcome is undesirable). 
The point estimate indicates the size of the effect (the 
further from the line, the greater the effect) and the CIs 
the range in which the true effect size might actually be. 
Hence, narrower CIs allow us to be more confident that 
the estimated effect size is close to the true effect size. It 
is important to consider, however, that even if the CIs do 
not cross the line of no effect, they may still only represent 
a clinically trivial increase or decrease in the outcome. 
For full interpretation of data, there are a whole raft of 
factors that should be considered together (not simply 
the statistical answer to your question); these issues 
are incorporated into the GRADE approach (Grading 
of Recommendations Assessment, Development and 
Evaluation) for assessing the evidence (15).
Taking into account the interpretation above, the forest 
plot in Figure 4 concludes that the new oral anticoagulants 
reduced the risk for a composite end point of stroke and 
systemic embolism compared to warfarin and were 
also associated with a lower risk for key secondary 
efficacy outcomes (ischemic and unidentified stroke, 
hemorrhagic stroke, all-cause mortality, and vascular 
mortality) compared to warfarin. It should be noted, 
however, that the upper CI for ischemic and unidentified 
stroke is very close to the line of no effect (0.99). When 
making decisions related to practice, it is important to 
consider that should the true effect lie at this point, then 
this would mean that newer anticoagulants only very 
marginally reduce the risk for a composite end point 
of stroke and systemic embolism as compared with 
warfarin.
Summary
In summary, systematic reviews (if well-conducted) can 
be an invaluable resource for providing an up-to-date and 
systematic summary of the current evidence for particular 
interventions. Overviews of systematic reviews are 
also useful because they provide summaries of groups 
of related systematic reviews (e.g., summarizing the 
evidence of the effectiveness of a number of different 
interventions for a certain outcome or disease). These 
can be particularly useful for informing policy decisions 
about which interventions are most effective. If a 
clinically important question has not yet been addressed 
by a systematic review, you might wish to consider 
undertaking one yourself. While systematic reviews 
can be challenging and time-consuming to conduct, 
they can also be extremely rewarding. Interacting with 
experts in the field will ensure the best approach and will 
help foster new collaborations in your area. Systematic 
reviews present the ideal opportunity to undertake in-
depth assessments of evidence relevant to your practice 
and have the potential to influence national guidelines in 
your area. Additionally they represent a chance to publish 
without (or before) undertaking primary research.
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